Showing results (1-10 of 82) with videos related to
Sort By:
Pageof 9
Seminars in Hematology|October 18, 2001
Chelation therapy in beta-thalassemia: an optimistic updateP J Giardina, R W GradySeminars in Hematology|October 1, 1995
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamineP J Giardina, R W GradyClinical and Experimental Immunology|November 1, 1985
Immunological abnormalities in thalassaemia major. I. A transfusion-related increase in circulating cytoplasmic immunoglobulin-positive cellsA N Akbar, P J Giardina, M W Hilgartner, et al.Advances in Experimental Medicine and Biology|January 1, 1994
Results from a phase I clinical trial of HBEDR W Grady, A D Salbe, M W Hilgartner, et al.British Journal of Haematology|April 1, 1985
Disproportionate lymphoid cell subsets in thalassaemia major: the relative contributions of transfusion and splenectomyR W Grady, A N Akbar, P J Giardina, et al.Clinical and Experimental Immunology|November 1, 1987
Modulation of the defective natural killer activity seen in thalassaemia major with desferrioxamine and alpha-interferonA N Akbar, P A Fitzgerald-Bocarsly, P J Giardina, et al.The Journal of Infectious Diseases|August 17, 2000
Effect of transfusional iron overload on immune responseS Cunningham-Rundles, P J Giardina, R W Grady, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1986
Decreased natural killer activity in thalassemia major: a possible consequence of iron overloadA N Akbar, P A Fitzgerald-Bocarsly, M de Sousa, et al.The Urologic Clinics of North America|September 14, 2000
Current management of prepubertal yolk sac tumors of the testisR W GradyJournal of Immunology (Baltimore, Md. : 1950)|June 1, 1987
HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemiaM Robert-Guroff, P J Giardina, W G Robey, et al.Pageof 9